article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

As I’ve been blogging about this for a couple months now, I’m really trying to find anyone who loves these things. Drew: I’ve published a draft version of it on the blog. You take their age, their gender, you take their chronic conditions. And then again, individualizing it to the patient.

IT 139
article thumbnail

Pharmacists in Florida (and Elsewhere): Waive Prescribing Red Flags at Your Peril

FDA Law Blog

By Larry K. District Court for the District of Texas on Zarzamora Healthcare LLC for repeatedly dispensing opioids and other controlled substances “by filling prescriptions while ignoring red flags.” 21 C.F.R. §§ 1306.04(a), a), 1306.06.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law Blog

Currently, individual Medicare Part D plan sponsors negotiate rebates but the government is explicitly prohibited from interfering in those negotiations. One proposal is a cap on out-of-pocket costs, primarily to help beneficiaries with expensive chronic conditions that can face large, even catastrophic, out-of-pocket spending every year.